| Revision as of 11:35, 6 November 2005 editBluebot (talk | contribs)349,597 editsm Bringing "External links" and "See also" sections in line with Manual of Style recommendations.← Previous edit | Revision as of 05:19, 7 April 2006 edit undoJHeuser (talk | contribs)48 editsm +deNext edit → | ||
| Line 17: | Line 17: | ||
| {{treatment-stub}} | {{treatment-stub}} | ||
| ] | ] | ||
| ] | |||
Revision as of 05:19, 7 April 2006
Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to act by noradrenergic autoreceptor and heteroreceptor antagonism combined with specific serotonergic antagonism. This results in increases in both noradrenergic and specific serotonergic transmission.
Examples of NaSSAs include:
- Mirtazapine (Remeron®, Zispin®, Avanza®, Norset®, Remergil®)
NaSSAs are said to have fewer side-effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with NaSSAs.
See also
External links
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |